CD19-CD28 costimulatory bispecific antibody plus glofitamab in R/R B-NHL: a phase 1 dose-escalation study.
A novel antibody combination produces strong remission rates in blood cancers, opening options for people who didn't respond to prior treatments.
The trial evaluated a CD19-CD28 costimulatory bispecific antibody combined with glofitamab. The combination produced complete response rates of 42.4% in aggressive and 89.5% in indolent lymphoma, with cytokine release syndrome occurring in 53.8% of patients.
What the study was
- Study design
- Phase I dose-escalation clinical trial
- Population
- 52 heavily pretreated patients with relapsed or refractory B-cell non-Hodgkin lymphoma
- Sample size
- 52
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Blood advances
Why it surfaced
The novel combination has promising early efficacy and pharmacodynamic evidence, but phase I size and nonrandomized design limit certainty
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.